Non-alcoholic fatty liver disease and psoriasis: So far, so near

World Journal of Hepatology

Volumn 7, Issue 3, 2015, Pages 315-326

  Ganzetti, Giulia ^a   Campanati, Anna ^a   Offidani, Annamaria ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Adipocytokines; Adipose tissue; Biologic therapies; Non alcoholic fatty liver disease; Nonbiologic therapies; Psoriasis

Indexed keywords

EID: 84928944377     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i3.315     Document Type: Article

References (126)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271 [PMID: 17658397]
2. Ganzetti G, Campanati A, Scocco V, Brugia M, Tocchini M, Liberati G, Giuliodori K, Brisigotti V, Offidani A. The potential effect of the tumour necrosis factor-α inhibitors on vitamin D status in psoriatic patients. Acta Derm Venereol 2014; 94: 715-717 [PMID:24789007 DOI: 10.2340/00015555-1801]
3. Boehncke WH, Boehncke S. More than skin-deep: the many dimensions of the psoriatic disease. Swiss Med Wkly 2014; 144:w13968 [PMID: 24764145 DOI: 10.4414/smw.2014.13968,]
4. Esposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? Nutr Metab Cardiovasc Dis 2004; 14: 228-232 [PMID: 15673055]
5. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40 Suppl 1: S17-S29 [PMID: 16540762]
6. Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol 2014; 7: 119-132 [PMID: 24790463 DOI: 10.2147/CCID.S44843,]
7. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28:27-38 [PMID: 17690317]
8. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395 [PMID: 15565570]
9. Papatheodoridis GV, Goulis J, Christodoulou D, Manolakopoulos S, Raptopoulou M, Andrioti E, Alexandropoulos N, Savvidou S, Papachristou A, Zervou E, Seferiadis K, Kousidou P, Vogiatzakis E, Tsianos E. High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity. Eur J Gastroenterol Hepatol 2007; 19: 281-287 [PMID: 17353691]
10. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-728 [PMID: 16287793]
11. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73 [PMID: 17553036]
12. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231 [PMID: 11961152]
13. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350 [PMID: 20879883 DOI: 10.1056/NEJMra0912063]
14. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899-905 [PMID: 15795412]
15. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, Conti M, Huet S, Ba N, Buffet C, Bedossa P. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34:738-744 [PMID: 11584370]
16. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010; 103: 71-83 [PMID:19914930 DOI: 10.1093/qjmed/hcp158]
17. Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol 2014; 7: 221-239 [PMID: 25045276 DOI: 10.2147/ CEG.S62831]
18. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008; 582: 97-105 [PMID: 18053812]
19. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004; 33: 283-303 [PMID:15158520]
20. Sozio MS, Liangpunsakul S, Crabb D. The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis. Semin Liver Dis 2010; 30: 378-390 [PMID: 20960377 DOI:10.1055/s-0030-1267538]
21. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease:pathology and pathogenesis. Annu Rev Pathol 2010; 5: 145-171 [PMID: 20078219 DOI: 10.1146/annurev-pathol-121808-102132]
22. Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007; 132: 2191-2207 [PMID: 17498512]
23. Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 2004; 432: 1027-1032 [PMID:15616563]
24. Wenk KS, Arrington KC, Ehrlich A. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol 2011; 25: 383-391 [PMID: 20840346 DOI: 10.1111/j.1468-3083.2010.03841]
25. Campanati A, Ganzetti G, Di Sario A, Damiani A, Sandroni L, Rosa L, Benedetti A, Offidani A. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol 2013; 48:839-846 [PMID: 23065020 DOI: 10.1007/s00535-012-0678-9]
26. Teunissen MBM, Piskin G, Res PCJM, De Groot M, Picavet D, De Rie MA, Bos JD. State of the art in the immunopathogenesis of psoriasis. G Ital Dermatol Venerol 2007; 142: 229-242. Available from: URL: http://www.minervamedica.it/en/journals/dermatologiavenereologia/ article.php?cod=R23Y2007N03A0229
27. Pauls K, Schön M, Kubitza RC, Homey B, Wiesenborn A, Lehmann P, Ruzicka T, Parker CM, Schön MP. Role of integrin alphaE(CD103)beta7 for tissue-specific epidermal localization of CD8+ T lymphocytes. J Invest Dermatol 2001; 117: 569-575 [PMID:11564161]
28. Driessen RJ, Bisschops LA, Adang EM, Evers AW, Van De Kerkhof PC, De Jong EM. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol 2010; 162: 1324-1329 [PMID:20163420 DOI: 10.1111/j.1365-2133.2010.09693]
29. Neiman AN, Porter S, Gelfand JM. The epidemiology of psoriasis. Expert Rev Dermatol 2006; 1:63-75
30. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004; 51: 704-708 [PMID: 15523347]
31. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284 [PMID: 11255325]
32. Onumah N, Kircik LH. Psoriasis and its comorbidities. J Drugs Dermatol 2012; 11: s5-10 [PMID: 22644770]
33. Torres T, Bettencourt N. Psoriasis: the visible killer. Rev Port Cardiol 2014; 33: 95-99 [PMID: 24525359 DOI: 10.1016/j.repc.2013.06.017]
34. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, Margolis DJ, Strom BL. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-1499 [PMID: 18086997]
35. Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis 2007; 17:684-698 [PMID: 17560098]
36. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008; 51: 1947-1953 [PMID:18762907 DOI: 10.1007/s00125-008-1135-4]
37. Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008; 7: 563-572 [PMID: 18561588]
38. Offidani AM, Ferretti G, Taus M, Simonetti O, Dousset N, Valdiguie P, Curatola G, Bossi G. Lipoprotein peroxidation in adult psoriatic patients. Acta Derm Venereol Suppl (Stockh) 1994; 186:38-40 [PMID: 8073834]
39. Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ. Lipoproteins and their subfractions in psoriatic arthritis:identification of an atherogenic profile with active joint disease. Ann Rheum Dis 2000; 59: 904-909 [PMID: 11053070]
40. Armstrong AW, Lin SW, Chambers CJ, Sockolov ME, Chin DL. Psoriasis and hypertension severity: results from a case-control study. PLoS One 2011; 6: e18227 [PMID: 21479272 DOI: 10.1371/ journal.pone.0018227]
41. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978; 99: 469-475 [PMID: 708620]
42. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, Ståhle-Bäckdahl M. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230 [PMID: 15117115]
43. Lin YC, Dalal D, Churton S, Brennan DM, Korman NJ, Kim ES, Husni ME. Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis. Arthritis Care Res (Hoboken) 2014; 66: 97-103 [PMID: 23983044]
44. Capeau J. Insulin resistance and steatosis in humans. Diabetes Metab 2008; 34: 649-657 [PMID: 19195626 DOI: 10.1016/ S1262-3636(08)74600-7]
45. Mallbris L, Ritchlin CT, Ståhle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006; 8:355-363 [PMID: 16973109]
46. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835 [PMID:17052489]
47. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298:321-328 [PMID: 17021763]
48. Lonardo A, Loria P, Carulli N. Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI. ST.E.N.A. study. Dig Liver Dis 2001; 33: 86-87 [PMID: 11303985]
49. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854 [PMID: 17393509]
50. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010; 42: 320-330 [PMID: 20207596 DOI: 10.1016/j.dld.2010.01.016]
51. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-764 [PMID: 19560226 DOI: 10.1016/ j.jhep.2009.04.020]
52. van der Voort EA, Koehler EM, Dowlatshahi EA, Hofman A, Stricker BH, Janssen HL, Schouten JN, Nijsten T. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol 2014; 70: 517-524 [PMID: 24373781 DOI: 10.1016/j.jaad.2013.10.044]
53. Carrascosa JM, Rocamora V, Fernandez-Torres RM, Jimenez-Puya R, Moreno JC, Coll-Puigserver N, Fonseca E. Obesity and psoriasis:inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr 2014; 105: 31-44 [PMID: 23177976 DOI: 10.1016/j.ad.2012.08.003]
54. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and metaanalysis of observational studies. Nutr Diabetes 2012; 2: e54 [PMID:23208415 DOI: 10.1038/nutd.2012.26]
55. Koppe SW. Obesity and the liver: nonalcoholic fatty liver disease. Transl Res 2014; 164: 312-322 [PMID: 25028077 DOI: 10.1016/ j.trsl.2014.06.008]
56. Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm 2010; 2010: pii: 289645 [PMID: 20706689 DOI: 10.1155/2010/289645]
57. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses 2006; 67: 768-773 [PMID: 16781085]
58. Das UN. Is obesity an inflammatory condition? Nutrition 2001; 17:953-966 [PMID: 11744348]
59. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556 [PMID: 15181022]
60. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54: 254-260 [PMID: 7033275]
61. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010; 316: 129-139 [PMID: 19723556 DOI: 10.1016/j.mce.2009.08.018]
62. Campanati A, Ganzetti G, Marra M, Bonfigli A, Giuliodori K, Testa R, Offidani A. Serum levels of adipocytokines in psoriatic patients receiving TNF-alpha inhibitors: results of a retrospective analysis. Intern J Dermatol 2014; In press
63. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006; 64: 355-365 [PMID: 16584505]
64. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003; 27 Suppl 3: S53-S55 [PMID:14704746]
65. Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 619-638, x [PMID: 15331067]
66. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-2119 [PMID:7738178]
67. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412-421 [PMID: 18081738]
68. Pietrzak AT, Zalewska A, Chodorowska G, Krasowska D, Michalak-Stoma A, Nockowski P, Osemlak P, Paszkowski T, Roliński JM. Cytokines and anticytokines in psoriasis. Clin Chim Acta 2008; 394: 7-21 [PMID: 18445484 DOI: 10.1016/ j.cca.2008.04.005]
69. Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008; 159: 1207-1208 [PMID:18795929 DOI: 10.1111/j.1365-2133.2008.08823.x]
70. Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol 2011; 20: 81-87 [PMID: 21255085 DOI:10.1111/j.1600-0625.2010.01210.x]
71. Saraceno R, Schipani C, Mazzotta A, Esposito M, Di Renzo L, De Lorenzo A, Chimenti S. Effect of anti-tumor necrosis factoralpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008; 57: 290-295 [PMID: 18400510 DOI: 10.1016/ j.phrs.2008.02.006]
72. Hui E, Xu A, Bo Yang H, Lam KS. Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines. J Diabetes Investig 2013; 4: 413-425 [PMID: 24843689 DOI:10.1111/jdi.12093]
73. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380: 24-30 [PMID: 17343838]
74. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fatderived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100 [PMID:12840063]
75. Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, Yoshimatsu H. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004; 40: 177-184 [PMID: 15239101]
76. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60: 313-326 [PMID:21040935 DOI: 10.1016/j.metabol.2010.09.003]
77. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116:1784-1792 [PMID: 16823476]
78. Targher G, Bertolini L, Scala L, Poli F, Zenari L, Falezza G. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxf) 2004; 61: 700-703 [PMID: 15579183]
79. Krueger G, Ellis CN. Psoriasis--recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005; 53:S94-S100 [PMID: 15968269]
80. Rácz E, Prens EP. Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. Expert Rev Mol Med 2009; 11: e38 [PMID: 20003607 DOI: 10.1017/ S146239940900129X]
81. Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-671 [PMID: 10766253]
82. Dekker JM, Funahashi T, Nijpels G, Pilz S, Stehouwer CD, Snijder MB, Bouter LM, Matsuzawa Y, Shimomura I, Heine RJ. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008; 93: 1489-1496 [PMID: 18211973 DOI:10.1210/jc.2007-1436]
83. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin--the classical, resistin--the controversical, adiponectin--the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19:525-546 [PMID: 16311215]
84. Wang Y, Chen J, Zhao Y, Geng L, Song F, Chen HD. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 2008; 158: 1134-1135 [PMID: 18294316 DOI: 10.1111/ j.1365-2133.2008.08456.x]
85. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, Figueiredo A, Teixeira F, Castro E, Rocha-Pereira P, Santos-Silva A. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol 2010; 24: 1386-1394 [PMID: 20337818 DOI: 10.1111/j.1468-3083.2010.03647.x]
86. Abenavoli L, Luigiano C, Guzzi PH, Milic N, Morace C, Stelitano L, Consolo P, Miraglia S, Fagoonee S, Virgilio C, Luzza F, De Lorenzo A, Pellicano R. Serum adipokine levels in overweight patients and their relationship with non-alcoholic fatty liver disease. Panminerva Med 2014; 56: 189-193 [PMID: 24994581]
87. Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnarsson SI, Steinsson JT, Elder JT, Valdimarsson H. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008; 159: 342-350 [PMID: 18547319 DOI: 10.1111/j.1365-2133.2008.08655.x]
88. Hosoda H, Kojima M, Mizushima T, Shimizu S, Kangawa K. Structural divergence of human ghrelin. Identification of multiple ghrelin-derived molecules produced by post-translational processing. J Biol Chem 2003; 278: 64-70 [PMID: 12414809]
89. Genc H, Dogru T, Kara M, Tapan S, Ercin CN, Acikel C, Karslioglu Y, Bagci S. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann Hepatol 2013; 12: 548-555 [PMID: 23813132]
90. Machado MV, Coutinho J, Carepa F, Costa A, Proença H, Cortez-Pinto H. How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2012; 24: 1166-1172 [PMID: 22735605 DOI:10.1097/MEG.0b013e32835609b0]
91. Gutierrez-Grobe Y, Villalobos-Blasquez I, Sánchez-Lara K, Villa AR, Ponciano-Rodríguez G, Ramos MH, Chavez-Tapia NC, Uribe M, Méndez-Sánchez N. High ghrelin and obestatin levels and low risk of developing fatty liver. Ann Hepatol 2010; 9: 52-57 [PMID:20308723]
92. Ozdemir M, Yüksel M, Gökbel H, Okudan N, Mevlitoğlu I. Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin. J Dermatol 2012; 39: 443-448 [PMID:22300284 DOI: 10.1111/j.1346-8138.2011.01497.x]
93. Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res 2009; 58: 727-736 [PMID: 19543691 DOI: 10.1007/s00011-009-0060-4]
94. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24:278-301 [PMID: 12788800]
95. Kaur S, Zilmer K, Kairane C, Kals M, Zilmer M. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008; 159: 1364-1367 [PMID: 18652586 DOI: 10.1111/ j.1365-2133.2008.08759.x]
96. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135: 1-8 [PMID: 14678257]
97. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease:Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006; 131: 934-945 [PMID: 16952562]
98. Tang Y, Bian Z, Zhao L, Liu Y, Liang S, Wang Q, Han X, Peng Y, Chen X, Shen L, Qiu D, Li Z, Ma X. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol 2011; 166: 281-290 [PMID: 21985374 DOI: 10.1111/j.1365-2249.2011.04471.x]
99. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008; 103: 1372-1379 [PMID: 18510618 DOI: 10.1111/ j.1572-0241.2007.01774.x]
100. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99:1497-1502 [PMID: 15307867]
101. Mrowietz U, Steinz K, Gerdes S. Psoriasis: to treat or to manage? Exp Dermatol 2014; 23: 705-709 [PMID: 24815425 DOI: 10.1111/ exd.12437]
102. Papoutsaki M, Costanzo A. Treatment of psoriasis and psoriatic arthritis. BioDrugs 2013; 27 Suppl 1: 3-12 [PMID: 23990277 DOI:10.1007/BF03325637]
103. Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, Shin DB, Attor R, Troxel AB, Gelfand JM. Psoriasis severity and the prevalence of major medical comorbidity: a populationbased study. JAMA Dermatol 2013; 149: 1173-1179 [PMID:23925466 DOI: 10.1001/jamadermatol.2013.5015]
104. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303:1-10 [PMID: 20857129 DOI: 10.1007/s00403-010-1080-1]
105. Ng LC, Lee YY, Lee CK, Wong SM. A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia. Int J Dermatol 2013; 52:102-105 [PMID: 23278617 DOI: 10.1111/j.1365-4632.2011.05436.x]
106. Berends MA, Snoek J, de Jong EM, Van Krieken JH, de Knegt RJ, van Oijen MG, van de Kerkhof PC, Drenth JP. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int 2007; 27: 639-645 [PMID: 17498249]
107. Erarslan E, Ekiz F, Uz B, Koca C, Turkcu UO, Bayrak R, Delibasi T. Effects of erdosteine on cyclosporine-A-induced hepatotoxicity in rats. Drug Chem Toxicol 2011; 34: 32-37 [PMID: 20954827 DOI:10.3109/01480545.2010.483519]
108. Silva FS, Ribeiro MP, Santos MS, Rocha-Pereira P, Santos-Silva A, Custódio JB. Acitretin affects bioenergetics of liver mitochondria and promotes mitochondrial permeability transition: potential mechanisms of hepatotoxicity. Toxicology 2013; 306: 93-100 [PMID: 23384448]
109. Mansouri B, Patel M, Menter A. Biological therapies for psoriasis. Expert Opin Biol Ther 2013; 13: 1715-1730 [PMID: 24160990 DOI: 10.1517/14712598.2013.853739]
110. Dubois Declercq S, Pouliot R. Promising new treatments for psoriasis. ScientificWorldJournal 2013; 2013: 980419 [PMID:23935446 DOI: 10.1155/2013/980419]
111. Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, Priori R, Valesini G. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1519-1520 [PMID: 16162908]
112. Iwamoto S, Kido M, Aoki N, Nishiura H, Maruoka R, Ikeda A, Okazaki T, Chiba T, Watanabe N. TNF-α is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression. Clin Immunol 2013; 146: 15-25 [PMID:23178752 DOI: 10.1016/j.clim.2012.10.008]
113. Cingoz O. Ustekinumab. MAbs 2009; 1: 216-221 [PMID:20069753]
114. Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, Mascelli MA. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 2011; 3: 535-545 [PMID: 22123062]
115. Shibata S, Tada Y, Hau C, Tatsuta A, Yamamoto M, Kamata M, Karakawa M, Asano Y, Mitsui H, Sugaya M, Kadono T, Saeki H, Kanda N, Sato S. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol 2011; 164: 667-670 [PMID:21062267]
116. Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother 2011; 12: 2041-2054 [PMID:21736530 DOI: 10.1517/14656566.2011.590475]
117. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22: 341-344 [PMID: 18005022]
118. Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 2002; 114: 1004-1007 [PMID: 12635469]
119. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003; 25:2487-2505 [PMID: 14667953]
120. Lestre S, Diamantino F, Veloso L, Fidalgo A, Ferreira A. Effects of etanercept treatment on lipid profile in patients with moderate-tosevere chronic plaque psoriasis: a retrospective cohort study. Eur J Dermatol 2011; 21: 916-920 [PMID: 21983007 DOI: 10.1684/ ejd.2011.1548]
121. Puig L, Strohal R, Fuiman J, Pedersen R, Szumski A, Koenig AS, Robertson D, Drexel H. Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment. J Dermatolog Treat 2014; 25: 470-481 [PMID: 24219012 DOI: 10.3109/09546634.2013.848260]
122. Bacchetti T, Campanati A, Ferretti G, Simonetti O, Liberati G, Offidani AM. Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment. Br J Dermatol 2013; 168:984-989 [PMID: 23614561 DOI: 10.1111/bjd.12144]
123. Marra M, Campanati A, Testa R, Sirolla C, Bonfigli AR, Franceschi C, Marchegiani F, Offidani A. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol 2007; 20: 731-736 [PMID: 18179745]
124. Gisondi P, Conti A, Galdo G, Piaserico S, De Simone C, Girolomoni G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol 2013; 168: 1124-1127 [PMID: 23320916 DOI:10.1111/bjd.12235]
125. Kargulewicz A, Stankowiak-Kulpa H, Grzymisławski M. Dietary recommendations for patients with nonalcoholic fatty liver disease. Prz Gastroenterol 2014; 9: 18-23 [PMID: 24868294 DOI: 10.5114/ pg.2014.40845]
126. Rolland C, Hession M, Broom I. Effect of weight loss on adipokine levels in obese patients. Diabetes Metab Syndr Obes 2011; 4:315-323 [PMID: 21887104 DOI: 10.2147/DMSO.S22788]